Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Tvardi Therapeutics (TVRD) Shares Outstanding (Weighted Average) (2016 - 2025)

Tvardi Therapeutics' Shares Outstanding (Weighted Average) history spans 13 years, with the latest figure at $7.4 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 188.2% to $7.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.4 million, a 188.2% increase, with the full-year FY2025 number at $7.4 million, up 188.2% from a year prior.
  • Shares Outstanding (Weighted Average) hit $7.4 million in Q4 2025 for Tvardi Therapeutics, down from $9.4 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for TVRD hit a ceiling of $54.7 million in Q3 2024 and a floor of $1.5 million in Q1 2024.
  • Historically, Shares Outstanding (Weighted Average) has averaged $33.6 million across 5 years, with a median of $50.1 million in 2021.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): plummeted 97.19% in 2024 and later surged 188.2% in 2025.
  • Tracing TVRD's Shares Outstanding (Weighted Average) over 5 years: stood at $50.7 million in 2021, then tumbled by 91.18% to $4.5 million in 2022, then increased by 0.92% to $4.5 million in 2023, then crashed by 42.95% to $2.6 million in 2024, then surged by 188.2% to $7.4 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for TVRD at $7.4 million in Q4 2025, $9.4 million in Q3 2025, and $8.2 million in Q2 2025.